Promethazine detailed information

Jump to navigation Jump to search
Promethazine detailed information
Error creating thumbnail: File missing
Clinical data
Pregnancy
category
  • AU: C
  • US: C (Risk not ruled out)
Routes of
administration
Oral, rectal, IV, IM
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability88% absorbed but after first-pass metabolism reduced to 25% absolute bioavailability
Protein binding93%
MetabolismHepatic glucuronidation and sulfoxidation
Elimination half-life16-19 hours
ExcretionRenal and biliary
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC17H20N2S
Molar mass284.425 g/mol

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Promethazine is a first-generation H1 receptor antagonist antihistamine and antiemetic medication. It is a prescription drug in the United States, but is available over the counter in the United Kingdom, Switzerland, and many other countries (brand names Phenergan®, Promethegan®, Romergan, Fargan®, Prothiazine®).

Promethazine also has strong anticholinergic and sedative/hypnotic effects. Previously it was used as an antipsychotic, although it is generally not administered for this purpose now; promethazine has only approximately 1/10 of the antipsychotic strength of chlorpromazine.

Indications

Contraindications

  • Promethazine should not be given to children under two years of age; there is potential for fatal respiratory depression in this age group.
  • Hypersensitivity to Phenothiazines
  • Closed angle glaucoma
  • Intoxication with alcohol or other central depressants
  • Severe hypotension or shock
  • Coma due to any reason
  • Severely impaired liver function
  • Urine hesitancy due to enlargement of the prostate gland

Side effects

Typical side effects are:

  • Blurred vision
  • Confusion in the elderly
  • Drowsiness, dizziness, fatigue, more rarely vertigo
  • Dry mouth
  • Seizures (extremely rare)
  • Neuroleptic malignant syndrome (extremely rare)
  • Respiratory depression in patients under age of 2 and in those with severely compromised pulmonal function
  • Constipation

Dosage

Depending on disease and clinical condition (age, liver function):

  • Mild to moderate cases of agitation: 25–50 mg orally, 3 to 4 times daily
  • Insomnia: depending upon severity, 25–100 mg orally at bedtime

In pediatric patients doses as low as 5–10 mg, 3 times daily may suffice. For precise dosing syrup forms exist.

As an anti-emetic:

  • Adult: 6.25 mg IV, or 12.5 mg IM
  • Pediatric (greater than 2 years old): 0.25 mg/kg IV/ IM

Laboratory examinations

All patients should have their blood pressure measured frequently. During long-term therapy, blood cell counts, liver function studies, EKG, and EEG are recommended. The intervals should be determined according to the risk profile of the patient.

Recreational use

Promethazine is sometimes used as a recreational drug in conjunction with Codeine in prescription cough syrup. The mixture of Sprite and cough syrup with codeine, which is known as "purple drank", is popularized in the rap world, especially in the Houston area.[1]

External links

References

  • Basic and Clinical Pharmacology, 9th ed (2004). Katzung, Bertram G. pp. 264–265.

Template:Antipruritics

de:Promethazin hu:Prometazin nl:Promethazine nn:Prometazin sv:Prometazin th:โปรเมทาซีน


  1. Peters Ronald J. Jr. (2003). "Beliefs and social norms about codeine and promethazine hydrochloride cough syrup (CPHCS) onset and perceived addiction among urban Houstonian adolescents: an addiction trend in the city of lean". Journal of drug education. 33 (4): 415–25. PMID 15237866,Error: Bad DOI specified!. Unknown parameter |coauthors= ignored (help)

Template:WH Template:WS